Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456012 | 0.95 | MMP1 (0.33) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL7551872 | 0.90 | MMP1 (0.42) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5668111 | 0.86 | LMNA (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL16914934 | 0.86 | PDE4A (0.40) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL10360445 | 0.84 | LMNA (0.33) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL7096392 | 0.83 | LMNA (0.38) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL4603930 | 0.83 | LMNA (0.38) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL491478 | 0.81 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL4603634 | 0.81 | MAPT (0.37) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL15145984 | 0.80 | USP2 (0.45) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142618-A1 | KETOGENIC SACCHARIDES | BTG INTERNATIONAL LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-7758744-B2 | Dual glucose-turbidimetric analytical sensors | ZWEIG STEPHEN ELIOT | 2010-07-20 | — | — | US | disclosed |
| US-20070225252-A1 | Ketogenic Saccharides | BTG INTERNATIONAL LIMITED (GB) | 2007-09-27 | — | — | US | disclosed |
| EP-1778212-A2 | KETOGENIC SACCHARIDES | KETOCYTONYX INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060051738-A1 | Dual glucose-turbidimetric analytical sensors | ZWEIG STEPHEN E | 2006-03-09 | — | — | US | disclosed |
| WO-2006012490-A2 | KETOGENIC SACCHARIDES | KETOCYTONYX INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-6984307-B2 | Dual glucose-hydroxybutyrate analytical sensors | ZWEIG STEPHEN ELIOT | 2006-01-10 | — | — | US | disclosed |
| US-20030068666-A1 | Dual glucose-hydroxybutyrate analytical sensors | ZWEIG STEPHEN ELIOT (US) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225252-A1 | Ketogenic Saccharides | MGAM, KHK, GCKR | LMNA 1866/4885L3MBTL1 1721/4885PDE4A 3784/4885 |
| US-20120142618-A1 | KETOGENIC SACCHARIDES | MGAM, GCKR, KHK | LMNA 1722/4885L3MBTL1 1776/4885PDE4A 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.